<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189069</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-583</org_study_id>
    <nct_id>NCT03189069</nct_id>
  </id_info>
  <brief_title>A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage</brief_title>
  <official_title>Real-World Comparisons of Bleeding Among Novel Oral Anticoagulant (NOAC)-Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage, Who Newly Initiated Novel Oral Anticoagulation Therapies or Were Treated With Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the risk of major bleeding and&#xD;
      stroke/systemic embolism (SE) among novel oral anti-coagulant (OAC) naïve and warfarin naïve&#xD;
      Medicare Advantage patients with non-valvular atrial fibrillation (NVAF) treated with&#xD;
      apixaban, dabigatran, rivaroxaban, or warfarin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2016</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">36000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Patients prescribed apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients prescribed dabigatran</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients prescribed rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients prescribed warfarin</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Treatment for NVAF patients</description>
    <arm_group_label>Patients prescribed apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Treatment for NVAF patients</description>
    <arm_group_label>Patients prescribed dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Treatment for NVAF patients</description>
    <arm_group_label>Patients prescribed rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Treatment for NVAF patients</description>
    <arm_group_label>Patients prescribed warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be selected from the MORE Registry according to the inclusion/exclusion&#xD;
        criteria. Four different cohorts will be evaluated: patients who were prescribed warfarin,&#xD;
        apixaban, dabigatran or rivaroxaban. Only users of oral anticoagulant treatment from&#xD;
        January 1, 2013 to January 1, 2016 will be included in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Had at least 1 pharmacy claim for warfarin, apixaban, dabigatran, or rivaroxaban&#xD;
             during the identification period (01-Jan-2013 through 31-Dec-2015)&#xD;
&#xD;
          -  Had continuous health plan enrollment with medical and pharmacy benefits for 6 months&#xD;
             pre-index date (baseline period)&#xD;
&#xD;
          -  Had continuous health plan enrollment with medical and pharmacy benefits for at least&#xD;
             1 month following index date&#xD;
&#xD;
          -  Had at least 1 medical claim for atrial fibrillation any time before or on index date&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Had medical claims with a diagnosis code for rheumatic mitral valvular heart disease,&#xD;
             mitral valve stenosis or heart valve replacement/transplant during the 6-month&#xD;
             baseline period&#xD;
&#xD;
          -  Had medical claims with a diagnosis code for dialysis, kidney transplant, or end-stage&#xD;
             chronic kidney disease during the 6 month baseline period&#xD;
&#xD;
          -  Had medical claims indicating a diagnosis of venous thromboembolism during the 6-month&#xD;
             baseline period&#xD;
&#xD;
          -  Had claims indicating a diagnosis or procedure code of hip or knee replacement surgery&#xD;
             within 6 weeks prior to the index date&#xD;
&#xD;
          -  Had claims for a diagnosis or procedure code for reversible atrial fibrillation&#xD;
&#xD;
          -  Had medical claims indicating pregnancy during the study period&#xD;
&#xD;
          -  Had a pharmacy claim for warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban&#xD;
             during the 6-month baseline period&#xD;
&#xD;
          -  Had &gt; 1 oral anticoagulant prescription claim on the index date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

